**Table 2. Distribution of Trial Designs by Disease Category and Sex Inclusion Criteria**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Disease Category** | **Total Trials** | **Both Sexes n (%)** | **Female Only n (%)** | **Male Only n (%)** |
| COVID-19 | 310 | 309 (99.7) | 1 (0.3) | 0 (0.0) |
| HIV/AIDS | 653 | 559 (85.6) | 33 (5.1) | 61 (9.3) |
| Cancer | 59 | 55 (93.2) | 2 (3.4) | 2 (3.4) |
| Cardiovascular | 13 | 13 (100.0) | 0 (0.0) | 0 (0.0) |
| Infectious Disease | 102 | 99 (97.1) | 3 (2.9) | 0 (0.0) |
| Respiratory | 29 | 29 (100.0) | 0 (0.0) | 0 (0.0) |
| Mental Health | 3 | 3 (100.0) | 0 (0.0) | 0 (0.0) |
| Diabetes | 1 | 1 (100.0) | 0 (0.0) | 0 (0.0) |
| Other | 655 | 623 (95.1) | 22 (3.4) | 9 (1.4) |
| Total | 1,825 | 1,691 (92.7) | 61 (3.3) | 72 (3.9) |

*Note: Percentages may not sum to 100% due to rounding. This table shows the distribution of trial designs, demonstrating how different approaches to sex inclusion combine to achieve overall statistical equity in representation.*